All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
HONG KONG – South Korean startup Orum Therapeutics Inc. has a shot at effectively blocking RAS gene function with an innovative technology co-developed with Ajou University in South Korea and last week raised $8 million in a series A round to advance work in oncology indications.